Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial
Rojas, J., de Lazzari, E., Negredo, E., Domingo, P., Paredes, R., Clotet, B. , et al. (2021). Efficacy and safety … Read More
